Bristol-Myers Squibb Award Goes to Folkman

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

NEW YORK--Judah Folkman, MD, who first theorized that tumors form and metastasize by means of angiogenesis, is the winner of the 18th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.

NEW YORK--Judah Folkman, MD, who first theorized that tumors formand metastasize by means of angiogenesis, is the winner of the18th annual Bristol-Myers Squibb Award for Distinguished Achievementin Cancer Research.

In 1971, Dr. Folkman reported the isolation of the first angiogenicfactor, a substance that induces blood vessel growth. In 1984,he and his colleagues Yuen Shing and Michael Klagsbrun purifiedthe first tumor-derived angiogenic factor, and Dr. Folkman laterdiscovered the first angiogenesis inhibitor.

Dr. Folkman is Julia Dyckman Andrus Professor of Pediatric Surgery,Harvard Medical School, and director of the Surgical ResearchLaboratory, Children's Hospital, Boston.

The company also announced the recipients of the 1995 Bristol-MyersSquibb Unrestricted Cancer Research Grants--Indiana UniversityCancer Center and the National Cancer Institute, Milan.

Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content